We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Six-Gene Score Improves Prognosis Prediction in Acute Myeloid Leukemia

By LabMedica International staff writers
Posted on 26 Oct 2026

Acute myeloid leukemia (AML) is a blood cancer with outcomes that can vary widely from one patient to another. More...

This variability complicates prognosis despite the laboratory information available from bone marrow sampling that patients already undergo. New findings offer a potential way to refine this assessment, demonstrating that the activity of six genes may help stratify AML patients by their survival prospects.

The Center for Genomic Regulation (CRG) in Barcelona developed PHFScore, a six-gene scoring system that combines the activity of CARMIL1, HOPX, ALDH1A1, CALR, STAR, and PHF19. Within this signature, CARMIL1, HOPX, and ALDH1A1 were more active in patients with poor outcomes, while CALR, STAR, and PHF19 were less active.

The work began by examining PHF19, a gene involved in keeping other genes switched off as cells differentiate from immature to mature states. To investigate its role, researchers introduced a leukemia-causing gene into mouse blood cells with and without PHF19. Cells lacking PHF19 formed more colonies in laboratory experiments, took hold more easily following transplantation into mice, and remained in an immature, stem-cell-like state.

Building on these experiments, the team developed the score by repeatedly comparing laboratory findings in mice with patient records to identify genes that behaved consistently in both. The molecular pattern observed in mice was also present in human AML datasets.

Among younger adults treated for AML, patients with the lowest PHF19 levels had shorter survival than those with the highest levels and were less likely to enter remission after standard chemotherapy. Fewer than half of patients with the lowest levels entered remission, compared with up to 85% of those with the highest levels.

The study took five years to complete and was published in Science Advances on October 23, 2026. It was led at CRG, with single-cell expertise and technological support from CRG’s Genomics Unit and Flow Cytometry Unit. The researchers said PHFScore could contribute to future prognostic test development, and that measuring six genes may be simpler and cheaper than reading a broader genetic profile.

“PHF19 on its own already tells us something about how patients will fare, but combining it with five other genes is a dramatic improvement which gives us more accurate information for AML prognosis,” said ICREA research professor Luciano Di Croce, senior author of the study and researcher at the CRG.

Related Links
 Center for Genomic Regulation


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Urinalysis Solution
UN-9000
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.